Compositions and methods for inhibiting the biological activity of soluble biomolecules
Inventors
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Assignees
Member
NaNoticsNaNotics is developing a new class of nanomedicine focused on the selective depletion of harmful soluble proteins implicated in cancer and other diseases. The company's injectable nanoparticle platform is designed to target and clear pathogenic soluble molecules from circulation without affecting essential membrane-bound forms, offering an innovative therapeutic approach for previously undruggable targets. The technology is modular, allowing rapid adaptation to new disease indications, and is supported by a strong patent portfolio and collaborative development with leading medical institutions.
NaNotics is developing a new class of nanomedicine focused on the selective depletion of harmful soluble proteins implicated in cancer and other diseases. The company's injectable nanoparticle platform is designed to target and clear pathogenic soluble molecules from circulation without affecting essential membrane-bound forms, offering an innovative therapeutic approach for previously undruggable targets. The technology is modular, allowing rapid adaptation to new disease indications, and is supported by a strong patent portfolio and collaborative development with leading medical institutions.
Publication Number
US-12685758-B2
Publication Date
2026-07-21
Expiration Date
Abstract
The disclosure provides, among other things, compositions that bind to and inhibit the biological activity of soluble biomolecules, as well as pharmaceutical compositions thereof. Also provided herein are a number of applications (e.g., therapeutic applications) in which the compositions are useful.
Core Innovation
The invention relates to compositions and methods for treating or preventing conditions by sequestering soluble biomolecules in circulation using engineered particles. The particles include an immobilized, selective binding agent that binds a target biomolecule and renders the bound biomolecule inert by preventing interactions with cognate ligands/receptors, thereby scavenging the target biomolecule.
In representative embodiments, the soluble target biomolecules include decoy receptors such as soluble TNF receptors and soluble IL-2 receptors, as well as other soluble cytokine receptors and death receptors. The invention further describes particles having shapes and sizes configured to circulate in the vasculature, and particle architectures designed to control binding agent presentation in a way intended to reduce agent-cell receptor interactions and reduce soluble biomolecule-cognate ligand interaction.
The invention additionally describes coatings and clearance strategies associated with the particles, including hydrophilic coatings to reduce nonspecific interactions and aggregation. It also describes clearance agent strategies for renal, hepatobiliary, and phagocytic clearance, including modulation of phagocytosis, and includes broad pharmaceutical formulations and administration routes for delivering the particle compositions.
The documented applications discussed include cancer immune dis-inhibition via scavenging shed soluble TNF receptors and IL-2 receptors, detoxification, and antiviral therapy. The disclosure also includes representative particle manufacturing discussion and in vivo pharmacokinetics/efficacy testing in mouse cancer models.
Claims Coverage
The partial content identifies one independent claim. It sets out a cancer treatment method that uses a vasculature-circulating particle with a selectively binding, agent-presenting surface and a coating that reduces agent-cell interactions, resulting in scavenging of a target biomolecule.
Scavenging target biomolecule with a vasculature-circulating particle
Administering a composition comprising a particle, wherein the particle is shaped and sized to circulate in the vasculature of the subject and thereby scavenges the target biomolecule.
Selective binding agent immobilized on the particle
The particle comprises an agent that selectively binds to a target biomolecule.
Coating that reduces agent-cell interactions
The particle comprises a coating that reduces interactions between the agent and a cell.
Cancer treatment using scavenging
A method of treating cancer in a subject in need thereof, comprising administering the composition such that the target biomolecule is scavenged.
Across the provided independent claim, the core claim coverage centers on cancer treatment by administering a particle that selectively binds a target biomolecule and circulates in vasculature, where a coating reduces agent-cell interactions, leading to scavenging of the target biomolecule.
Stated Advantages
Enables scavenging of the target biomolecule in a cancer treatment method by preventing interactions with cognate ligands/receptors.
Reduces interactions between the agent and a cell, and reduces soluble biomolecule-cognate ligand interaction.
Reduces nonspecific interactions and aggregation through hydrophilic coatings.
Supports clearance via renal, hepatobiliary, and phagocytic pathways, including modulation of phagocytosis.
Documented Applications
Cancer immune dis-inhibition via scavenging shed soluble TNF receptors and IL-2 receptors.
Detoxification.
Antiviral therapy.
Mouse cancer model evaluation including representative in vivo pharmacokinetics/efficacy testing.
Interested in licensing this patent?